Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > So, what do I think? Or say?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(192)
•••
Comment by craighenryon Feb 20, 2021 11:20am
127 Views
Post# 32618571

RE:RE:RE:RE:RE:RE:RE:So, what do I think? Or say?

RE:RE:RE:RE:RE:RE:RE:So, what do I think? Or say?
zwerp2000 wrote: As usual, your posts are nothing but mindless ramblings. If Bioaf is kicking my a$$ then presumably it's kicking your a$$ and your man crush, JDs a$$ too. Maybe that's why you're so angry. You've been with this stock for so many years and now you realize it's not working out like you thought it would. Maybe your DD stinks?


NOPE!!! Nice try coward!! I am still up about 45k on my bioasis investment!!!! Was up almost a 100k when we hit the .70s!! I unlike you know what I am invested in. I spent hours last week trying to decipher the Prothena earnings and how that ties into bioasis. I was on the phone with regardless for many hours as well going over bioasis. You are such a loser. You NEED people to SPOON FEED YOU!!!!!!! Do us all a favor and crawl back under your bridge.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities